Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Bio2RDF identifier

NCT01941316

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01941316

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01941316

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

112

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01941316 arm group 83166deea18ac1bee85252cd1161d932 [clinicaltrials_resource:NCT01941316/arm-group/83166deea18ac1bee85252cd1161d932]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... ith this combination therapy.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Study of Carfilzomib With Irin ...... mall Cell Lung Cancer Patients

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:65fe1ac331253823256c7eefdbca187d]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:b3de54e1d0c1ccf267f272f148845ebd]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:111135a8812533aa069563ac392057c9]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:42d926ed401b3a7eaa2db53e08cafadc]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:6ca9526653a289bdd4ef9456629bd108]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:82a607de8cb581e45b31240a28eebdd4]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:bfcc9cdc7e9852f81931148f21b5ceb8]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:d3623a7b0232dee59810aa5fda45f48c]

Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers. 28 Days [clinicaltrials_resource:e82d2f42c90c3dc0e94b9b16fb270810]

collaborator [clinicaltrials_vocabulary:collaborator]

Cancer Research and Biostatistics Clinical Trials Consortium [clinicaltrials_resource:1916b9ba6bc1db8b9b9daf6cf45e1585]

completion date [clinicaltrials_vocabulary:completion-date]

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Small cell lung cancer ...... b and 125mg/m2 of Irinotecan.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01941316 [clinicaltrials_resource:e30c251c684e39c33295d17d7de4243c]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Irinotecan [clinicaltrials_resource:725b21135a98384e644352e1f83a5278]

Carfilzomib [clinicaltrials_resource:aae888aecc32bb599f172c24e7f9f105]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Irinotecan [clinicaltrials_resource:e51064865358a8412329fc174471d012]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Carfilzomib

http://www.w3.org/2001/XMLSchema#string

Cervical Cancer

http://www.w3.org/2001/XMLSchema#string

Esophageal Cancer

http://www.w3.org/2001/XMLSchema#string

Gastric Cancer

http://www.w3.org/2001/XMLSchema#string

Irinotecan

http://www.w3.org/2001/XMLSchema#string

Non Small Cell Lung Cancer

http://www.w3.org/2001/XMLSchema#string

Ovarian Cancer

http://www.w3.org/2001/XMLSchema#string

Small Cell Lung Cancer

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Cancer Research and Biostatistics Clinical Trials Consortium [clinicaltrials_resource:1916b9ba6bc1db8b9b9daf6cf45e1585]

location [clinicaltrials_vocabulary:location]

Cancer Treatment Centers of America, Western Regional Medical Center [clinicaltrials_resource:3373e184aa2cf94ee24a40ce359de7cf]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01941316

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Phase 1b/II Trial of Carfilzom ...... or Platinum-based Chemotherapy

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CRAB CTC 11-001

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Susanne M Arnold, MD [clinicaltrials_resource:c76b64f202578e31297e24bf92c67ef6]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Susanne M Arnold, MD [clinicaltrials_resource:440669ac40f61285376fa2db7fae95a5]

overall official [clinicaltrials_vocabulary:overall-official]

Susanne M Arnold, MD [clinicaltrials_resource:a1f5c7cad004c9a99407732cd8f119df]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:965595316c5ae1a4521a298d475eb908]

phase [clinicaltrials_vocabulary:phase]

Phase 1/Phase 2 [clinicaltrials_resource:72d8d9eabd48f679d5dffa41c4dd93f7]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

CAR-IST-553

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Cancer Research and Biostatistics Clinical Trials Consortium [clinicaltrials_resource:1916b9ba6bc1db8b9b9daf6cf45e1585]

start date [clinicaltrials_vocabulary:start-date]

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01941316 study design [clinicaltrials_resource:735b05f0f518a1fb80d1f920ff58d422]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01941316

verification date [clinicaltrials_vocabulary:verification-date]

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01941316

http://www.w3.org/2001/XMLSchema#string